McCoy RG, Van Houten HK, Karaca-Mandic P, et al. - The outcomes demonstrated that individuals with cardiovascular disease, heart failure (HF), and nephropathy, for whom evidence implies a greater likelihood of benefiting from glucagon-like peptide 1 receptor agonists (GLP-1RA) and/or sodium-glucose cotransporter 2 inhibitors (SGLT2i) therapy, were less likely to start these drugs. According to the findings. noticing this treatment/benefit paradox, which was most pronounced in non-White and older individuals, may help decrease the morbidity correlated with these conditions.

• Researchers distinguished 75,395 patients who started GLP-1RA, 58,234 who started SGLT2i, and 91,884 who started dipeptidyl peptidase 4 inhibitors (DPP-4i).

• It has been reported that individuals with prior MI, cerebrovascular disease, or nephropathy were less likely to start GLP-1RA rather than DPP-4i in comparison with individuals without these conditions (RRR 0.83 [95% CI 0.78–0.88] for MI, RRR 0.77 [0.74–0.81] for cerebrovascular disease, and RRR 0.87 [0.84–0.91] for nephropathy).

• Patients with HF or nephropathy were less likely to start SGLT2i (RRR 0.83 [0.80–0.87] for HF and RRR 0.57 [0.55–0.60] for nephropathy).

• Non-White and older patients were less likely to start both medication classes.